DETERMINATION OF SAMPLE SIZE 3.6.1. Stage 1 Sample Size A total of approximately 100 subjects were initially planned to be enrolled and to receive the treatment regimen indicated for Stage 1 (SL-701/GMCSF/imiquimod cream). Enrollment of patients into Stage 1 was interrupted on April 7, 2015 to enable review and evaluation of safety and efficacy (46 subjects were enrolled in Stage 1). Following that review, the study protocol was amended to incorporate Stage 2, in which a different dosing regimen was tested (SL- 701/bevacizumab/poly-ICLC), and therefore the initial assumptions for the sample size were no longer relevant. The initially planned sample size of 100 patients was based on the following assumptions for the coprimary endpoints of OS-12 and ORR:  OS-12: A sample size of 100 with a one-sided Type-1 error rate of 1.25% would provide approximately 82% power to reject the null hypothesis that the OS- 12 rate is ≤25% if the true OS- 12 is ≥ 40%.  ORR: A sample size of 100 with a one-sided Type-1 error rate of 1.25% would provide approximately 92% power to reject the null hypothesis that the ORR is ≤10% if the true ORR is ≥ 25% DocuSign Envelope ID: B3F56764-C440-4885-BA44-7578C4A73DB3 Stemline Therapeutics, Inc. Protocol: STML- 701-0114 Version 3.0, 10-JUL-2015 (Amendment 2) Statistical Analysis Plan Page 18 of 63 3.7. TREATMENT ASSIGNMENT & BLINDING All patients in this open-label study will receive treatment with SL-701/GM-CSF/i miquimod in Stage 1 and with SL-701/poly-ICLC and bevacizumab in Stage 2. 3.8. ADMINISTRATION OF STUDY MEDICATION SL-701 consists of HLA-A2 restricted epitope peptides, MPS-380 (IL- 13Rα2 345-353:1A9V ), MPS-381 (EphA2 883-891 ), MPS-486 (Survivin 95-104:3M ), derived from 3 antigens that are overexpressed by glioma relative to normal tissues. SL-701 also includes MPS-199, a peptide that functions as a helper T-cell epitope from the Tetanus Toxoid, Tet A830. A 1.0 ml dose of the SL-701 emulsion contains 0.3 mg each of the MPS-380, MPS-381, and MPS-486 peptides and 0.2 mg of the MPS- 199 peptide. 3.8.1. Stage 1 Study Medication Administration A complete dose of study medication consists of treatment with a sequence of 3 agents —SL-701 emulsion subcutaneous (SC) injection, GM-SCF injection and imiquimod topical cream. Topical application of imiquimod cream at the injection site is repeated 24 hours following after each SL - 701 emulsion injection. Patients will be treated with SL-701 every 14 days. Each patient will be treated with SC injections of SL-701 emulsion every 14 days initially for 12 doses, followed by administrations every 28 days. 3.8.2. Stage 2 Study Medication Administration A complete dose of study medication consists of treatment with a sequence of 2 agents —SL-701 emulsion injection, and poly-ICLC intramuscular (IM) injection, within an approximate 20 minute time frame. Patients will also receive IV bevacizumab. Patients will be treated with SL-701 emulsion/poly-ICLC twice weekly for the initial 2 w eeks, once every 7 days during the subsequent 3 doses, and every 14 days for the remaining 9 doses (16 doses total) through Week 22, and every 4 weeks thereafter. Bevacizumab will be administered every 2 weeks, subsequent to the administration of SL-701/poly-ICLC. 3.9.